

How does obesity contribute to SUI, and what are the treatment strategies?

新竹台大醫院

吳晉睿




婦產部 吳晉睿醫師


- 新竹台大分院專任醫師
- 台大醫院癌醫兼任醫師
- 教育部定助理教授
- 婦女泌尿醫學會專科醫師



τ_{UI}



Severe UI



Obesity does impact the urinary incontinence

Epidemiology

表1、成人過重及肥胖盛行率(以身體質量指數為標準)(2017-2020)

性別	年齡 (歲)	樣本數 (人)	BMI ≥ 35	$30 \leq \text{BMI} < 35$	$27 \leq \text{BMI} < 30$	$24 \leq \text{BMI} < 27$
			比率 (%)	比率 (%)	比率 (%)	比率 (%)
男性	19-30	258	3.64	9.00	10.63	26.41
	31-44	292	3.26	13.21	17.87	31.17
	45-64	651	1.12	9.17	19.08	30.79
	65 -	1052	0.52	6.26	15.35	33.97
	≥ 19	2253	2.12	9.78	16.45	30.52
女性	19-30	275	1.48	7.31	5.86	17.91
	31-44	322	1.48	6.72	9.43	18.30
	45-64	698	0.39	8.09	11.57	24.83
	65 -	962	1.21	8.58	17.59	32.78
	≥ 19	2257	1.03	7.67	10.95	23.15

58.87% 過重
11.90% 肥胖

□□↓□□ 過重
□↓□□ 肥胖

資料來源：2017-2020年國民營養健康調查。

註.有效樣本數採實際完訪樣本數之最大可利用值，分析結果經加權調整。

製表日期：2022/06/15

Why obesity impact urinary incontinence ?



- $f_t \partial \frac{3}{4} \ddot{I} \frac{3}{4} \times \text{H} \frac{3}{4} \mid \times - \text{O} \text{ñ} \ddot{I} \Gamma \frac{3}{4} \frac{3}{4} \frac{3}{4}$

- $\text{ç} \frac{3}{4} \Gamma \ddot{O} \frac{3}{4} \rightarrow \frac{3}{4} \clubsuit \text{E} \frac{3}{4} \partial \frac{3}{4} \tau$

- $\partial \frac{3}{4} \frac{3}{4} \ddot{N} \Gamma \frac{3}{4} \text{ñ} \partial \frac{3}{4} \frac{3}{4} \text{ç} \frac{3}{4} \acute{Z} \tau \frac{3}{4} \frac{3}{4}$

- $9 - \tau \tau \frac{3}{4} \partial \frac{3}{4} \frac{3}{4} \frac{3}{4} \frac{3}{4} \frac{3}{4} \text{ñ} \tau \check{e} \frac{3}{4}$

- $c - \frac{3}{4} - \tau \frac{3}{4} \text{H} \frac{3}{4} \frac{3}{4} \frac{3}{4} \partial \frac{3}{4}$



IAP is associated with weight, BMI and SAD ($r=0.59, 0.58, 0.78$ respectively; $P<0.0001$)

The Relationship of Body Mass Index to Intra-abdominal Pressure as Measured by Multichannel Cystometry

K. L. Noblett, J. K. Jensen, D. R. Ostergard

Long Beach Memorial Medical Center, Long Beach, California, USA

Table 3. Pearson correlation coefficients

IAP*/BMI	0.76 ($P < 0.0001$)
IVP [†] /BMI	0.71 ($P < 0.0001$)
IAP [§] /BMI	0.73 ($P < 0.0001$)

*intra-abdominal pressure (both transvaginal and transrectal)

† intravesical pressure

^sintra-abdominal pressure (transvaginal)

Why obesity leads to IAP?

Mechanism

Increased visceral fat

Mechanical compression

Reduced abdominal wall compliance

Elevated diaphragm

Postural changes

Physical activities

Impact on IAP

Direct volume increase inside abdomen

Continuous elevated baseline pressure

Less ability to accommodate fat volume

Compresses abdominal organs downward

Further reduction in abdominal space

Higher pressure peaks with minimal effort




Table 2.
Pelvic Floor Dysfunctions: Prevalence and Mean Scores

Variable	Obese (BMI \geq 35) (n=358)		Control (BMI<35) (n=37)		Age-Adjusted		Covariant-Adjusted	
	Prevalence (%)	Mean Score	Prevalence (%)	Mean Score	Prevalence <i>P</i> -value(1)	Mean Scores <i>P</i> -value(2)	Prevalence <i>P</i> -value(3)	Mean Scores <i>P</i> -value(4)
PFDI-20								
POPDI	66	18.1	14	1.4	<.001	<.001	<.001	<.001
CRADI	68	17.0	8	0.8	<.001	<.001	<.001	<.001
UDI	81	32.5	5	0.8	<.001	<.001	<.001	<.001
Total	91	67.5	22	2.9	<.001	<.001	<.001	<.001
PFIQ-7								
IIQ	46	15.1	0	0	<.001	<.001	<.001	<.001
CRADI	25	8.2	0	0	<.001	0.01	<.001	0.01
POPDI	24	9.3	0	0	<.001	0.01	<.001	0.01
Total	53	32.6	0	0	<.001	<.001	<.001	<.001

Prevalence and degree of bother from pelvic floor disorders in obese women

Emily L. Whitcomb • Emily S. Lukacz •
Jean M. Lawrence • Charles W. Nager • Karl M. Luber





The more the obesity,
The more the pelvic symptoms
(SUI, OAB, POP ...)

Condition	Obese, BMI 30– 34.9 kg/m ² , N=690	Severely obese BMI 35– 39.9 kg/m ² , N=284	Morbidly obese BMI≥ 40 kg/m ² , N=181	<i>p</i>
Prolapse, <i>N</i> , % (95% CI)	48, 7.0 (5.3–9.1)	28, 9.9 (6.9–13.9)	23, 12.7 (8.6–18.4) ^a	0.040 ^b
VAS	73.2±19.9	72.5±20.1	66.8±18.6	0.422 ^c
Stress incontinence, <i>N</i> , % (95% CI)	135, 19.7 (16.9–22.9)	91, 32.3 (27.2–38.1) ^a	54, 30.2% (23.9–37.3) ^a	<0.001 ^c
VAS	66.3±14.8	65.1±14.2	64.5±14.2	0.699 ^b
Overactive bladder, <i>N</i> , % (95% CI)	136, 20.2 (17.3–23.4)	71, 26.1 (21.2–31.6)	46, 26.7 (20.7–33.8)	0.054 ^c
VAS	78.8±11.4	76.8±10.8	80.5±12.1	0.216 ^b
Anal incontinence, <i>N</i> , % (95% CI)	188, 27.2% (24.1–30.7)	93, 32.7% (27.6–38.4)	59, 32.6% (26.2–39.7)	0.178 ^c
VAS	42.0±17.9	42.4±17.9	41.5±13.6	0.955 ^b
Any PFD, <i>N</i> , % (95% CI)	292, 44.3 (40.6–48.1)	143, 52.6 (46.6–58.4) ^a	96, 56.8 (49.3–64.0) ^a	0.004 ^c


Table 3 Crude and adjusted odds ratios (95% CI) for the associations between degree of obesity (obese, severely obese, and morbidly obese) and each and any pelvic floor disorder

	POP	OAB	SUI	AI	Any PFD
Crude OR (95% CI)					
Obese (N=690)	1.00 (referent)	1.00 (referent)	1.00 (referent)	1.00 (referent)	1.00 (referent)
Severe (N=284)	1.46 (0.89–2.37)	1.38 (0.99–1.92)	1.93 (1.41–2.64)	1.29 (0.95–1.75)	1.38 (1.04–1.84)
Morbidly (N=181)	1.95 (1.15–3.31)	1.48 (1.01–2.17)	1.79 (1.24–2.59)	1.32 (0.93–1.89)	1.67 (1.19–2.35)
Adjusted OR (95% CI)					
Obese (N=690)	1.00 (referent)	1.00 (referent)	1.00 (referent)	1.00 (referent)	1.00 (referent)
Severe (N=284)	1.55 (0.92–2.60)	1.40 (0.98–1.99)	1.99 (1.43–2.78)	1.32 (0.96–1.82)	1.43 (1.05–1.93)
Morbidly (N=181)	2.09 (1.18–3.68)	1.66 (1.11–2.50)	1.87 (1.26–2.76)	1.39 (0.96–2.02)	1.75 (1.22–2.51)

SUI and **POP** are two main symptoms proportioned to the severity of obesity




The pelvic girdle of young females with underweight and healthy BMIs (N = 30) showed relatively **more upright ilium and prominent ischial spines** and relatively higher everted sacrum than those with overweight and obese BMIs.




Zucker Fatty(ZF) rat

- Genetic defect in the leptin receptor
- Hyperphagia
- Insulin resistance
- Hyperinsulinemia
- Hyperlipoproteinemia
- Obesity
- Not diabetes mellitus





Urethral striated muscles are less in ZF than ZL rats



Lipid accumulated within the urethral striated muscle myofibers in Zucker fatty (ZF) rats

Lean Adipose Tissue - Anti-inflammatory

Obese Adipose Tissue - Pro-inflammatory



- Macrophage: IL-10, Arginase, Catecholamines
- Eosinophil: IL-4, IL-13
- Treg cell: IL-10, TGF beta
- Th2 cell: IL-4, IL-5, IL-6, IL-10, IL-13

- Macrophage: TNF alpha, IL-1b, IL-6, IL-12
- Neutrophil: Elastases, Cathepsin G, Proteinase-3
- Mast cell: TNF alpha, IL-6, IFN gamma
- T cell: TNF alpha, IL-2, IFN gamma
- NKT cell: IFN gamma
- B cell: IgG antibody

Healthy adipocytes

Adipokines
Anti-inflammatory
Adiponectin
Chemerin (low expression)

Inflammation

Dysfunctional adipocytes

Obesity / High fat diet

Saturated Free Fatty Acid

Hypoxia

Cellular Senescence

Adipokines

Inflammatory
TNF alpha
MCP-1
etc.
Anti-inflammatory
Adiponectin

**Anti-inflammatory
Cytokine: IL-19, IL-10**

Inflammation

Immune cells
infiltration

Inflammatory
cytokines

Insulin
signaling

**Insulin
resistance**

Treatment strategies

- © Ćñ ěكـلـĉ³/۴♣
- Ä—تـليـکـلـĉñİ ΓⓈ³/۴ñÑ𐌹𐌺𐌾𐌿
- © کـلـĉñİ ΓⓈ³/۴ñÑ𐌹𐌺𐌾𐌿

Ten-year follow-up after the tension-free vaginal tape procedure

Thomas Aigmueller, MD; Gerda Trutnovsky, MD; Karl Tamussino, MD; Julia Kargl, MD; Anna Wittmann, MD; Milana Surtov, MD; Petra Kern, MD; Andrea Frudinger, MD; Paul Riss, MD; Vesna Bjelic-Radisic, MD

Results

Interview data were available for 67%; full clinical investigation was performed in 56% of patients. At 10 years, the clinical stress test was negative in 84%, slightly positive in 8.5%, and strongly positive in 4.3%. Subjectively, 57% of patients considered themselves “cured,” 23% “improved,” 6.4% “unchanged,” and 11% “worse.” Eleven of 141 (7.8%) had been reoperated in the interim. The rate of de novo urgency was 20%. Obesity seemed to be a risk factor for failure.

available at www.sciencedirect.com
journal homepage: www.europeanurology.com



European Association of Urology



Platinum Priority – Female Urology – Incontinence

Editorial by Firouz Daneshgari on pp. 947–948 of this issue

Tension-free Vaginal Tape for the Treatment of Urodynamic Stress Incontinence: Efficacy and Adverse Effects at 10-Year Follow-Up

Maurizio Serati^{a,*}, Fabio Ghezzi^a, Elena Cattoni^a, Andrea Braga^a, Gabriele Siesto^b, Marco Torella^c, Antonella Cromi^a, Domenico Vitobello^b, Stefano Salvatore^d

^a Department of Obstetrics and Gynecology, University of Insubria, Varese, Italy; ^b Department of Gynecology, IRCCS Humanitas Clinical Institute, Rozzano, Milan, Italy; ^c Department of Obstetrics and Gynecology, 2nd Faculty, Naples, Italy; ^d Department of Obstetrics and Gynecology, IRCCS San Raffaele Hospital, Milan, Italy

In 2010-2012, we observed that obesity seems to be a risk factor of TVT failure

Is Obesity a Risk Factor for Failure and Complications After Surgery for Incontinence and Prolapse in Women?

Rashel M. Haverkorn, B. Jill Williams, William S. Kubricht, III and Alex Gomelsky*

From the Department of Urology, University of Texas Southwestern, Dallas, Texas (RMH), Department of Urology, Louisiana State University Health Sciences Center, Shreveport (BJW, AG), and Urology Center for Women, Baton Rouge (WSK), Louisiana

	PP	
	BMI Less Than 30	BMI 30 or Greater
Pads/day:		
Preop	1.15	2.12
Postop	0.17	0.28
SEAPI:		
Preop	5.22	6.44
Postop	0.68	1.15
IIQ:		
Preop	8.23	11.19
Postop	1.01	1.50
UDI-6:		
Preop	7.02	8.39
Postop	0.97	1.55
VAS:		
Preop	2.85	2.25
Postop	9.27	9.05

	PP	
	BMI Less Than 30	BMI 30 or Greater
Mean mos followup	22.47	23.12
% Global cure	83.9	70.9
p Value	<0.001	
% SUI cure	91.9	81.2
p Value	<0.001	
% Would undergo surgery again*	96.9	97.4
% Would recommend to friend*	96.3	98.3

* All values p not significantly differ

BMI \geq 30 used more pads and lower SUIcure rate at 12 months



Contents lists available at ScienceDirect

European Journal of Obstetrics & Gynecology and Reproductive Biology

journal homepage: www.elsevier.com/locate/ejogrb

Single incision mid-urethral slings: impact of obesity on outcomes



Michele Meschia*, Gabriela Rossi, Silvia Bertini, Arianna Sommacal, Sara Foina, Francesca Sandretti, Pietro Barbacini

Department of Obstetrics and Gynecology, Azienda Ospedaliera di Legnano, Ospedale "G. Fornaroli", Magenta, Italy

One year objective and patient reported outcomes.

	Normal N=69	Overweight N=91	Obese N=36	P
Objective cure, n (%)	63 (91.3)	76 (83.5)	27 (75)	0.07 ^a
Change in ICI-SF, (pre-post) mean ± SD	−12.4 ± 3.7	−12.3 ± 3.8	−9.3 ± 5.1	<0.001 ^b
PGI-I, score 1–2, n (%)	65 (94)	80 (88)	26 (72)	0.006 ^c
Change in WIPSS, (pre-post) mean ± SD	−3.4 ± 4.2	−4 ± 4.8	−3.6 ± 5.3	0.71
Change in OAB symptoms, (pre-post) n, (%)	20–14 (−8%)	27–18 (−8%)	16–13 (−5%)	0.39

كك 3/4 × كك ٥ ٦ ٧ ٨ ٩ ١٠ ١١ ١٢ ١٣ ١٤ ١٥ ١٦ ١٧ ١٨ ١٩ ٢٠ ٢١ ٢٢ ٢٣ ٢٤ ٢٥ ٢٦ ٢٧ ٢٨ ٢٩ ٣٠ ٣١ ٣٢ ٣٣ ٣٤ ٣٥ ٣٦ ٣٧ ٣٨ ٣٩ ٤٠ ٤١ ٤٢ ٤٣ ٤٤ ٤٥ ٤٦ ٤٧ ٤٨ ٤٩ ٥٠ ٥١ ٥٢ ٥٣ ٥٤ ٥٥ ٥٦ ٥٧ ٥٨ ٥٩ ٦٠ ٦١ ٦٢ ٦٣ ٦٤ ٦٥ ٦٦ ٦٧ ٦٨ ٦٩ ٧٠ ٧١ ٧٢ ٧٣ ٧٤ ٧٥ ٧٦ ٧٧ ٧٨ ٧٩ ٨٠ ٨١ ٨٢ ٨٣ ٨٤ ٨٥ ٨٦ ٨٧ ٨٨ ٨٩ ٩٠ ٩١ ٩٢ ٩٣ ٩٤ ٩٥ ٩٦ ٩٧ ٩٨ ٩٩ ١٠٠ ١٠١ ١٠٢ ١٠٣ ١٠٤ ١٠٥ ١٠٦ ١٠٧ ١٠٨ ١٠٩ ١١٠ ١١١ ١١٢ ١١٣ ١١٤ ١١٥ ١١٦ ١١٧ ١١٨ ١١٩ ١٢٠ ١٢١ ١٢٢ ١٢٣ ١٢٤ ١٢٥ ١٢٦ ١٢٧ ١٢٨ ١٢٩ ١٣٠ ١٣١ ١٣٢ ١٣٣ ١٣٤ ١٣٥ ١٣٦ ١٣٧ ١٣٨ ١٣٩ ١٤٠ ١٤١ ١٤٢ ١٤٣ ١٤٤ ١٤٥ ١٤٦ ١٤٧ ١٤٨ ١٤٩ ١٥٠ ١٥١ ١٥٢ ١٥٣ ١٥٤ ١٥٥ ١٥٦ ١٥٧ ١٥٨ ١٥٩ ١٦٠ ١٦١ ١٦٢ ١٦٣ ١٦٤ ١٦٥ ١٦٦ ١٦٧ ١٦٨ ١٦٩ ١٧٠ ١٧١ ١٧٢ ١٧٣ ١٧٤ ١٧٥ ١٧٦ ١٧٧ ١٧٨ ١٧٩ ١٨٠ ١٨١ ١٨٢ ١٨٣ ١٨٤ ١٨٥ ١٨٦ ١٨٧ ١٨٨ ١٨٩ ١٩٠ ١٩١ ١٩٢ ١٩٣ ١٩٤ ١٩٥ ١٩٦ ١٩٧ ١٩٨ ١٩٩ ٢٠٠ ٢٠١ ٢٠٢ ٢٠٣ ٢٠٤ ٢٠٥ ٢٠٦ ٢٠٧ ٢٠٨ ٢٠٩ ٢١٠ ٢١١ ٢١٢ ٢١٣ ٢١٤ ٢١٥ ٢١٦ ٢١٧ ٢١٨ ٢١٩ ٢٢٠ ٢٢١ ٢٢٢ ٢٢٣ ٢٢٤ ٢٢٥ ٢٢٦ ٢٢٧ ٢٢٨ ٢٢٩ ٢٣٠ ٢٣١ ٢٣٢ ٢٣٣ ٢٣٤ ٢٣٥ ٢٣٦ ٢٣٧ ٢٣٨ ٢٣٩ ٢٤٠ ٢٤١ ٢٤٢ ٢٤٣ ٢٤٤ ٢٤٥ ٢٤٦ ٢٤٧ ٢٤٨ ٢٤٩ ٢٥٠ ٢٥١ ٢٥٢ ٢٥٣ ٢٥٤ ٢٥٥ ٢٥٦ ٢٥٧ ٢٥٨ ٢٥٩ ٢٦٠ ٢٦١ ٢٦٢ ٢٦٣ ٢٦٤ ٢٦٥ ٢٦٦ ٢٦٧ ٢٦٨ ٢٦٩ ٢٧٠ ٢٧١ ٢٧٢ ٢٧٣ ٢٧٤ ٢٧٥ ٢٧٦ ٢٧٧ ٢٧٨ ٢٧٩ ٢٨٠ ٢٨١ ٢٨٢ ٢٨٣ ٢٨٤ ٢٨٥ ٢٨٦ ٢٨٧ ٢٨٨ ٢٨٩ ٢٩٠ ٢٩١ ٢٩٢ ٢٩٣ ٢٩٤ ٢٩٥ ٢٩٦ ٢٩٧ ٢٩٨ ٢٩٩ ٣٠٠ ٣٠١ ٣٠٢ ٣٠٣ ٣٠٤ ٣٠٥ ٣٠٦ ٣٠٧ ٣٠٨ ٣٠٩ ٣١٠ ٣١١ ٣١٢ ٣١٣ ٣١٤ ٣١٥ ٣١٦ ٣١٧ ٣١٨ ٣١٩ ٣٢٠ ٣٢١ ٣٢٢ ٣٢٣ ٣٢٤ ٣٢٥ ٣٢٦ ٣٢٧ ٣٢٨ ٣٢٩ ٣٣٠ ٣٣١ ٣٣٢ ٣٣٣ ٣٣٤ ٣٣٥ ٣٣٦ ٣٣٧ ٣٣٨ ٣٣٩ ٣٤٠ ٣٤١ ٣٤٢ ٣٤٣ ٣٤٤ ٣٤٥ ٣٤٦ ٣٤٧ ٣٤٨ ٣٤٩ ٣٥٠ ٣٥١ ٣٥٢ ٣٥٣ ٣٥٤ ٣٥٥ ٣٥٦ ٣٥٧ ٣٥٨ ٣٥٩ ٣٦٠ ٣٦١ ٣٦٢ ٣٦٣ ٣٦٤ ٣٦٥ ٣٦٦ ٣٦٧ ٣٦٨ ٣٦٩ ٣٧٠ ٣٧١ ٣٧٢ ٣٧٣ ٣٧٤ ٣٧٥ ٣٧٦ ٣٧٧ ٣٧٨ ٣٧٩ ٣٨٠ ٣٨١ ٣٨٢ ٣٨٣ ٣٨٤ ٣٨٥ ٣٨٦ ٣٨٧ ٣٨٨ ٣٨٩ ٣٩٠ ٣٩١ ٣٩٢ ٣٩٣ ٣٩٤ ٣٩٥ ٣٩٦ ٣٩٧ ٣٩٨ ٣٩٩ ٤٠٠ ٤٠١ ٤٠٢ ٤٠٣ ٤٠٤ ٤٠٥ ٤٠٦ ٤٠٧ ٤٠٨ ٤٠٩ ٤١٠ ٤١١ ٤١٢ ٤١٣ ٤١٤ ٤١٥ ٤١٦ ٤١٧ ٤١٨ ٤١٩ ٤٢٠ ٤٢١ ٤٢٢ ٤٢٣ ٤٢٤ ٤٢٥ ٤٢٦ ٤٢٧ ٤٢٨ ٤٢٩ ٤٣٠ ٤٣١ ٤٣٢ ٤٣٣ ٤٣٤ ٤٣٥ ٤٣٦ ٤٣٧ ٤٣٨ ٤٣٩ ٤٤٠ ٤٤١ ٤٤٢ ٤٤٣ ٤٤٤ ٤٤٥ ٤٤٦ ٤٤٧ ٤٤٨ ٤٤٩ ٤٥٠ ٤٥١ ٤٥٢ ٤٥٣ ٤٥٤ ٤٥٥ ٤٥٦ ٤٥٧ ٤٥٨ ٤٥٩ ٤٦٠ ٤٦١ ٤٦٢ ٤٦٣ ٤٦٤ ٤٦٥ ٤٦٦ ٤٦٧ ٤٦٨ ٤٦٩ ٤٧٠ ٤٧١ ٤٧٢ ٤٧٣ ٤٧٤ ٤٧٥ ٤٧٦ ٤٧٧ ٤٧٨ ٤٧٩ ٤٨٠ ٤٨١ ٤٨٢ ٤٨٣ ٤٨٤ ٤٨٥ ٤٨٦ ٤٨٧ ٤٨٨ ٤٨٩ ٤٩٠ ٤٩١ ٤٩٢ ٤٩٣ ٤٩٤ ٤٩٥ ٤٩٦ ٤٩٧ ٤٩٨ ٤٩٩ ٥٠٠ ٥٠١ ٥٠٢ ٥٠٣ ٥٠٤ ٥٠٥ ٥٠٦ ٥٠٧ ٥٠٨ ٥٠٩ ٥١٠ ٥١١ ٥١٢ ٥١٣ ٥١٤ ٥١٥ ٥١٦ ٥١٧ ٥١٨ ٥١٩ ٥٢٠ ٥٢١ ٥٢٢ ٥٢٣ ٥٢٤ ٥٢٥ ٥٢٦ ٥٢٧ ٥٢٨ ٥٢٩ ٥٣٠ ٥٣١ ٥٣٢ ٥٣٣ ٥٣٤ ٥٣٥ ٥٣٦ ٥٣٧ ٥٣٨ ٥٣٩ ٥٤٠ ٥٤١ ٥٤٢ ٥٤٣ ٥٤٤ ٥٤٥ ٥٤٦ ٥٤٧ ٥٤٨ ٥٤٩ ٥٥٠ ٥٥١ ٥٥٢ ٥٥٣ ٥٥٤ ٥٥٥ ٥٥٦ ٥٥٧ ٥٥٨ ٥٥٩ ٥٦٠ ٥٦١ ٥٦٢ ٥٦٣ ٥٦٤ ٥٦٥ ٥٦٦ ٥٦٧ ٥٦٨ ٥٦٩ ٥٧٠ ٥٧١ ٥٧٢ ٥٧٣ ٥٧٤ ٥٧٥ ٥٧٦ ٥٧٧ ٥٧٨ ٥٧٩ ٥٨٠ ٥٨١ ٥٨٢ ٥٨٣ ٥٨٤ ٥٨٥ ٥٨٦ ٥٨٧ ٥٨٨ ٥٨٩ ٥٩٠ ٥٩١ ٥٩٢ ٥٩٣ ٥٩٤ ٥٩٥ ٥٩٦ ٥٩٧ ٥٩٨ ٥٩٩ ٦٠٠ ٦٠١ ٦٠٢ ٦٠٣ ٦٠٤ ٦٠٥ ٦٠٦ ٦٠٧ ٦٠٨ ٦٠٩ ٦١٠ ٦١١ ٦١٢ ٦١٣ ٦١٤ ٦١٥ ٦١٦ ٦١٧ ٦١٨ ٦١٩ ٦٢٠ ٦٢١ ٦٢٢ ٦٢٣ ٦٢٤ ٦٢٥ ٦٢٦ ٦٢٧ ٦٢٨ ٦٢٩ ٦٣٠ ٦٣١ ٦٣٢ ٦٣٣ ٦٣٤ ٦٣٥ ٦٣٦ ٦٣٧ ٦٣٨ ٦٣٩ ٦٤٠ ٦٤١ ٦٤٢ ٦٤٣ ٦٤٤ ٦٤٥ ٦٤٦ ٦٤٧ ٦٤٨ ٦٤٩ ٦٥٠ ٦٥١ ٦٥٢ ٦٥٣ ٦٥٤ ٦٥٥ ٦٥٦ ٦٥٧ ٦٥٨ ٦٥٩ ٦٦٠ ٦٦١ ٦٦٢ ٦٦٣ ٦٦٤ ٦٦٥ ٦٦٦ ٦٦٧ ٦٦٨ ٦٦٩ ٦٧٠ ٦٧١ ٦٧٢ ٦٧٣ ٦٧٤ ٦٧٥ ٦٧٦ ٦٧٧ ٦٧٨ ٦٧٩ ٦٨٠ ٦٨١ ٦٨٢ ٦٨٣ ٦٨٤ ٦٨٥ ٦٨٦ ٦٨٧ ٦٨٨ ٦٨٩ ٦٩٠ ٦٩١ ٦٩٢ ٦٩٣ ٦٩٤ ٦٩٥ ٦٩٦ ٦٩٧ ٦٩٨ ٦٩٩ ٧٠٠ ٧٠١ ٧٠٢ ٧٠٣ ٧٠٤ ٧٠٥ ٧٠٦ ٧٠٧ ٧٠٨ ٧٠٩ ٧١٠ ٧١١ ٧١٢ ٧١٣ ٧١٤ ٧١٥ ٧١٦ ٧١٧ ٧١٨ ٧١٩ ٧٢٠ ٧٢١ ٧٢٢ ٧٢٣ ٧٢٤ ٧٢٥ ٧٢٦ ٧٢٧ ٧٢٨ ٧٢٩ ٧٣٠ ٧٣١ ٧٣٢ ٧٣٣ ٧٣٤ ٧٣٥ ٧٣٦ ٧٣٧ ٧٣٨ ٧٣٩ ٧٤٠ ٧٤١ ٧٤٢ ٧٤٣ ٧٤٤ ٧٤٥ ٧٤٦ ٧٤٧ ٧٤٨ ٧٤٩ ٧٥٠ ٧٥١ ٧٥٢ ٧٥٣ ٧٥٤ ٧٥٥ ٧٥٦ ٧٥٧ ٧٥٨ ٧٥٩ ٧٦٠ ٧٦١ ٧٦٢ ٧٦٣ ٧٦٤ ٧٦٥ ٧٦٦ ٧٦٧ ٧٦٨ ٧٦٩ ٧٧٠ ٧٧١ ٧٧٢ ٧٧٣ ٧٧٤ ٧٧٥ ٧٧٦ ٧٧٧ ٧٧٨ ٧٧٩ ٧٨٠ ٧٨١ ٧٨٢ ٧٨٣ ٧٨٤ ٧٨٥ ٧٨٦ ٧٨٧ ٧٨٨ ٧٨٩ ٧٩٠ ٧٩١ ٧٩٢ ٧٩٣ ٧٩٤ ٧٩٥ ٧٩٦ ٧٩٧ ٧٩٨ ٧٩٩ ٨٠٠ ٨٠١ ٨٠٢ ٨٠٣ ٨٠٤ ٨٠٥ ٨٠٦ ٨٠٧ ٨٠٨ ٨٠٩ ٨١٠ ٨١١ ٨١٢ ٨١٣ ٨١٤ ٨١٥ ٨١٦ ٨١٧ ٨١٨ ٨١٩ ٨٢٠ ٨٢١ ٨٢٢ ٨٢٣ ٨٢٤ ٨٢٥ ٨٢٦ ٨٢٧ ٨٢٨ ٨٢٩ ٨٣٠ ٨٣١ ٨٣٢ ٨٣٣ ٨٣٤ ٨٣٥ ٨٣٦ ٨٣٧ ٨٣٨ ٨٣٩ ٨٤٠ ٨٤١ ٨٤٢ ٨٤٣ ٨٤٤ ٨٤٥ ٨٤٦ ٨٤٧ ٨٤٨ ٨٤٩ ٨٥٠ ٨٥١ ٨٥٢ ٨٥٣ ٨٥٤ ٨٥٥ ٨٥٦ ٨٥٧ ٨٥٨ ٨٥٩ ٨٦٠ ٨٦١ ٨٦٢ ٨٦٣ ٨٦٤ ٨٦٥ ٨٦٦ ٨٦٧ ٨٦٨ ٨٦٩ ٨٧٠ ٨٧١ ٨٧٢ ٨٧٣ ٨٧٤ ٨٧٥ ٨٧٦ ٨٧٧ ٨٧٨ ٨٧٩ ٨٨٠ ٨٨١ ٨٨٢ ٨٨٣ ٨٨٤ ٨٨٥ ٨٨٦ ٨٨٧ ٨٨٨ ٨٨٩ ٨٩٠ ٨٩١ ٨٩٢ ٨٩٣ ٨٩٤ ٨٩٥ ٨٩٦ ٨٩٧ ٨٩٨ ٨٩٩ ٩٠٠ ٩٠١ ٩٠٢ ٩٠٣ ٩٠٤ ٩٠٥ ٩٠٦ ٩٠٧ ٩٠٨ ٩٠٩ ٩١٠ ٩١١ ٩١٢ ٩١٣ ٩١٤ ٩١٥ ٩١٦ ٩١٧ ٩١٨ ٩١٩ ٩٢٠ ٩٢١ ٩٢٢ ٩٢٣ ٩٢٤ ٩٢٥ ٩٢٦ ٩٢٧ ٩٢٨ ٩٢٩ ٩٣٠ ٩٣١ ٩٣٢ ٩٣٣ ٩٣٤ ٩٣٥ ٩٣٦ ٩٣٧ ٩٣٨ ٩٣٩ ٩٤٠ ٩٤١ ٩٤٢ ٩٤٣ ٩٤٤ ٩٤٥ ٩٤٦ ٩٤٧ ٩٤٨ ٩٤٩ ٩٥٠ ٩٥١ ٩٥٢ ٩٥٣ ٩٥٤ ٩٥٥ ٩٥٦ ٩٥٧ ٩٥٨ ٩٥٩ ٩٦٠ ٩٦١ ٩٦٢ ٩٦٣ ٩٦٤ ٩٦٥ ٩٦٦ ٩٦٧ ٩٦٨ ٩٦٩ ٩٧٠ ٩٧١ ٩٧٢ ٩٧٣ ٩٧٤ ٩٧٥ ٩٧٦ ٩٧٧ ٩٧٨ ٩٧٩ ٩٨٠ ٩٨١ ٩٨٢ ٩٨٣ ٩٨٤ ٩٨٥ ٩٨٦ ٩٨٧ ٩٨٨ ٩٨٩ ٩٩٠ ٩٩١ ٩٩٢ ٩٩٣ ٩٩٤ ٩٩٥ ٩٩٦ ٩٩٧ ٩٩٨ ٩٩٩ ١٠٠٠ ١٠٠١ ١٠٠٢ ١٠٠٣ ١٠٠٤ ١٠٠٥ ١٠٠٦ ١٠٠٧ ١٠٠٨ ١٠٠٩ ١٠١٠ ١٠١١ ١٠١٢ ١٠١٣ ١٠١٤ ١٠١٥ ١٠١٦ ١٠١٧ ١٠١٨ ١٠١٩ ١٠٢٠ ١٠٢١ ١٠٢٢ ١٠٢٣ ١٠٢٤ ١٠٢٥ ١٠٢٦ ١٠٢٧ ١٠٢٨ ١٠٢٩ ١٠٣٠ ١٠٣١ ١٠٣٢ ١٠٣٣ ١٠٣٤ ١٠٣٥ ١٠٣٦ ١٠٣٧ ١٠٣٨ ١٠٣٩ ١٠٤٠ ١٠٤١ ١٠٤٢ ١٠٤٣ ١٠٤٤ ١٠٤٥ ١٠٤٦ ١٠٤٧ ١٠٤٨ ١٠٤٩ ١٠٥٠ ١٠٥١ ١٠٥٢ ١٠٥٣ ١٠٥٤ ١٠٥٥ ١٠٥٦ ١٠٥٧ ١٠٥٨ ١٠٥٩ ١٠٦٠ ١٠٦١ ١٠٦٢ ١٠٦٣ ١٠٦٤ ١٠٦٥ ١٠٦٦ ١٠٦٧ ١٠٦٨ ١٠٦٩ ١٠٧٠ ١٠٧١ ١٠٧٢ ١٠٧٣ ١٠٧٤ ١٠٧٥ ١٠٧٦ ١٠٧٧ ١٠٧٨ ١٠٧٩ ١٠٨٠ ١٠٨١ ١٠٨٢ ١٠٨٣ ١٠٨٤ ١٠٨٥ ١٠٨٦ ١٠٨٧ ١٠٨٨ ١٠٨٩ ١٠٩٠ ١٠٩١ ١٠٩٢ ١٠٩٣ ١٠٩٤ ١٠٩٥ ١٠٩٦ ١٠٩٧ ١٠٩٨ ١٠٩٩ ١١٠٠ ١١٠١ ١١٠٢ ١١٠٣ ١١٠٤ ١١٠٥ ١١٠٦ ١١٠٧ ١١٠٨ ١١٠٩ ١١١٠ ١١١١ ١١١٢ ١١١٣ ١١١٤ ١١١٥ ١١١٦ ١١١٧ ١١١٨ ١١١٩ ١١٢٠ ١١٢١ ١١٢٢ ١١٢٣ ١١٢٤ ١١٢٥ ١١٢٦ ١١٢٧ ١١٢٨ ١١٢٩ ١١٣٠ ١١٣١ ١١٣٢ ١١٣٣ ١١٣٤ ١١٣٥ ١١٣٦ ١١٣٧ ١١٣٨ ١١٣٩ ١١٤٠ ١١٤١ ١١٤٢ ١١٤٣ ١١٤٤ ١١٤٥ ١١٤٦ ١١٤٧ ١١٤٨ ١١٤٩ ١١٥٠ ١١٥١ ١١٥٢ ١١٥٣ ١١٥٤ ١١٥٥ ١١٥٦ ١١٥٧ ١١٥٨ ١١٥٩ ١١٦٠ ١١٦١ ١١٦٢ ١١٦٣ ١١٦٤ ١١٦٥ ١١٦٦ ١١٦٧ ١١٦٨ ١١٦٩ ١١٧٠ ١١٧١ ١١٧٢ ١١٧٣ ١١٧٤ ١١٧٥ ١١٧٦ ١١٧٧ ١١٧٨ ١١٧٩ ١١٨٠ ١١٨١ ١١٨٢ ١١٨٣ ١١٨٤ ١١٨٥ ١١٨٦ ١١٨٧ ١١٨٨ ١١٨٩ ١١٩٠ ١١٩١ ١١٩٢ ١١٩٣ ١١٩٤ ١١٩٥ ١١٩٦ ١١٩٧ ١١٩٨ ١١٩٩ ١٢٠٠ ١٢٠١ ١٢٠٢ ١٢٠٣ ١٢٠٤ ١٢٠٥ ١٢٠٦ ١٢٠٧ ١٢٠٨ ١٢٠٩ ١٢١٠ ١٢١١ ١٢١٢ ١٢١٣ ١٢١٤ ١٢١٥ ١٢١٦ ١٢١٧ ١٢١٨ ١٢١٩ ١٢٢٠ ١٢٢١ ١٢٢٢ ١٢٢٣ ١٢٢٤ ١٢٢٥ ١٢٢٦ ١٢٢٧ ١٢٢٨ ١٢٢٩ ١٢٣٠ ١٢٣١ ١٢٣٢ ١٢٣٣ ١٢٣٤ ١٢٣٥ ١٢٣٦ ١٢٣٧ ١٢٣٨ ١٢٣٩ ١٢٤٠ ١٢٤١ ١٢٤٢ ١٢٤٣ ١٢٤٤ ١٢٤٥ ١٢٤٦ ١٢٤٧ ١٢٤٨ ١٢٤٩ ١٢٥٠ ١٢٥١ ١٢٥٢ ١٢٥٣ ١٢٥٤ ١٢٥٥ ١٢٥٦ ١٢٥٧ ١٢٥٨ ١٢٥٩ ١٢٦٠ ١٢٦١ ١٢٦٢ ١٢٦٣ ١٢٦٤ ١٢٦٥ ١٢٦٦ ١٢٦٧ ١٢٦٨ ١٢٦٩ ١٢٧٠ ١٢٧١ ١٢٧٢ ١٢٧٣ ١٢٧٤ ١٢٧٥ ١٢٧٦ ١٢٧٧ ١٢٧٨ ١٢٧٩ ١٢٨٠ ١٢٨١ ١٢٨٢ ١٢٨٣ ١٢٨٤ ١٢٨٥ ١٢٨٦ ١٢٨٧ ١٢٨٨ ١٢٨٩ ١٢٩٠ ١٢٩١ ١٢٩٢ ١٢٩٣ ١٢٩٤ ١٢٩٥ ١٢٩٦ ١٢٩٧ ١٢٩٨ ١٢٩٩ ١٣٠٠ ١٣٠١ ١٣٠٢ ١٣٠٣ ١٣٠٤ ١٣٠٥ ١٣٠٦ ١٣٠٧ ١٣٠٨ ١٣٠٩ ١٣١٠ ١٣١١ ١٣١٢ ١٣١٣ ١٣١٤ ١٣١٥ ١٣١٦ ١٣١٧ ١٣١٨ ١٣١٩ ١٣٢٠ ١٣٢١ ١٣٢٢ ١٣٢٣ ١٣٢٤ ١٣٢٥ ١٣٢٦ ١٣٢٧ ١٣٢٨ ١٣٢٩ ١٣٣٠ ١٣٣١ ١٣٣٢ ١٣٣٣ ١٣٣٤ ١٣٣٥ ١٣٣٦ ١٣٣٧ ١٣٣٨ ١٣٣٩ ١٣٤٠ ١٣٤١ ١٣٤٢ ١٣٤٣ ١٣٤٤ ١٣٤٥ ١٣٤٦ ١٣٤٧ ١٣٤٨ ١٣٤٩ ١٣٥٠ ١٣٥١ ١٣٥٢ ١٣٥٣ ١٣٥٤ ١٣٥٥ ١٣٥٦ ١٣٥٧ ١٣٥٨ ١٣٥٩ ١٣٦٠ ١٣٦١ ١٣٦٢ ١٣٦٣ ١٣٦٤ ١٣٦٥ ١٣٦٦ ١٣٦٧ ١٣٦٨ ١٣٦٩ ١٣٧٠ ١٣٧١ ١٣٧٢ ١٣٧٣ ١٣٧٤ ١٣٧٥ ١٣٧٦ ١٣٧٧ ١٣٧٨ ١٣٧٩ ١٣٨٠ ١٣٨١ ١٣٨٢ ١٣٨٣ ١٣٨٤ ١٣٨٥ ١٣٨٦ ١٣٨٧ ١٣٨٨ ١٣٨٩ ١٣٩٠ ١٣٩١ ١٣٩٢ ١٣٩٣ ١٣٩٤ ١٣٩٥ ١٣٩٦ ١٣٩٧ ١٣٩٨ ١٣٩٩ ١٤٠٠ ١٤٠١ ١٤٠٢ ١٤٠٣ ١٤٠٤ ١٤٠٥ ١٤٠٦ ١٤٠٧ ١٤٠٨ ١٤٠٩ ١٤١٠ ١٤١١ ١٤١٢ ١٤١٣ ١٤١٤ ١٤١٥ ١٤١٦ ١٤١٧ ١٤١٨ ١٤١٩ ١٤٢٠ ١٤٢١ ١٤٢٢ ١٤٢٣ ١٤٢٤ ١٤٢٥ ١٤٢٦ ١٤٢٧ ١٤٢٨ ١٤٢٩ ١٤٣٠ ١٤٣١ ١٤٣٢ ١٤٣٣ ١٤٣٤ ١٤٣٥ ١٤٣٦ ١٤٣٧ ١٤٣٨ ١٤٣٩ ١٤٤٠ ١٤٤١ ١٤٤٢ ١٤٤٣ ١٤٤٤ ١٤٤٥ ١٤٤٦ ١٤٤٧ ١٤٤٨ ١٤٤٩ ١٤٥٠ ١٤٥١ ١٤٥٢ ١٤٥٣ ١٤٥٤ ١٤٥٥ ١٤٥٦ ١٤٥٧ ١٤٥٨ ١٤٥٩ ١٤٦٠ ١٤٦١ ١٤٦٢ ١٤٦٣ ١٤٦٤ ١٤٦٥ ١٤٦٦ ١٤٦٧ ١٤٦٨ ١٤٦٩ ١٤٧٠ ١٤٧١ ١٤٧٢ ١٤٧٣ ١٤٧٤ ١٤٧٥ ١٤٧٦ ١٤٧٧ ١٤٧٨ ١٤٧٩ ١٤٨٠ ١٤٨١ ١٤٨٢ ١٤٨٣ ١٤٨٤ ١٤٨٥ ١٤٨٦ ١٤٨٧ ١٤٨٨ ١٤٨٩ ١٤٩٠ ١٤٩١ ١٤٩٢ ١٤٩٣ ١٤٩٤ ١٤٩٥ ١٤٩٦ ١٤٩٧ ١٤٩٨ ١٤٩٩ ١٥٠٠ ١٥٠١ ١٥٠٢ ١٥٠٣

Why sling tends to fail in obese patients?

[illegible][illegible]


“It is possible that increased **intra-abdominal pressure** generated in obese women during routine daily activities may **stress the sling** repeatedly and earlier than in nonobese women. Thus, the sling may settle and incorporate into a **looser position**, and decrease the chance of retention.”

RM, Williams BJ, Kubricht WS, Gomelsky A (2011) Is Obesity a Risk Factor for Failure and Complications After Surgery for Incontinence and Prolapse in Women? J 7–992.


ORIGINAL ARTICLE

Weight Loss to Treat Urinary Incontinence in Overweight and Obese Women

[illegible]



Roux-en-Y gastric bypass (RYGB)



Sleeve gastrectomy (SG)

Original Investigation

Urinary Incontinence Before and After Bariatric Surgery

Leslee L. Subak, MD; Wendy C. King, PhD; Steven H. Belle, PhD, MScHyg; Jia-Yuh Chen, MS; Anita P. Courcoulas, MD, MPH; Faith E. Ebel, RD, MS, MPH; David R. Flum, MD, MPH; Saurabh Khandelwal, MD; John R. Pender, MD; Sheila K. Pierson, BS; Walter J. Pories, MD; Kristine J. Steffen, PharmD, PhD; Gladys W. Strain, PhD; Bruce M. Wolfe, MD; Alison J. Huang, MD, MAS

- Observational cohort study at 10 US hospitals
- Between February 21, 2005, and February 17, 2009
- 1-year weight loss of 29.5% (95% CI, 29.0%-30.1%)
- Define **at least weekly incontinence** of any type were considered to have prevalent incontinence.

Bariatric surgical procedure

Roux-en-Y gastric bypass	1111 (71.0)
Laparoscopic adjustable gastric band	387 (24.7)
Sleeve gastrectomy	33 (2.1)
Biliopancreatic diversion with duodenal switch	12 (0.8)
Banded gastric bypass	22 (1.4)


Variable	No./Total No. (%)			
	Baseline	Year 1	Year 2	Year 3
Women (n = 1565)				
Frequency of urinary incontinence episodes	(n = 1565)	(n = 1373)	(n = 1241)	(n = 1188)
Never	357 (22.8)	680 (49.5)	576 (46.4)	528 (44.4)
<Monthly	247 (15.8)	304 (22.1)	257 (20.7)	235 (19.8)
Monthly	189 (12.1)	139 (10.1)	119 (9.6)	135 (11.4)
Weekly	352 (22.5)	135 (9.8)	160 (12.9)	157 (13.2)
Daily	420 (26.8)	115 (8.4)	129 (10.4)	133 (11.2)
Prevalence of urinary incontinence at least weekly				
Any type	772/1565 (49.3)	250/1373 (18.2)	289/1241 (23.3)	290/1188 (24.4)
Stress type	646/1530 (42.2)	188/1357 (13.9)	211/1226 (17.2)	220/1169 (18.8)
Urgency type	505/1528 (33.0)	165/1359 (12.1)	204/1229 (16.6)	202/1174 (17.2)

- Year 1 urinary incontinence prevalence was significantly lower among women(18.3%; 95% CI,16.4%-20.4%)
- The 3-year prevalence was higher than the 1-year prevalence for women(24.8%; 95% CI, 21.8%-26.5%) but was substantially lower than baseline (P < .001 for all).

Review

The impact of bariatric surgery on urinary incontinence: a systematic review and meta-analysis

Yung Lee^{*,†,‡} , James Yu^{†,‡} , Kari A.O. Tikkinen[§], Michał Pędziwiatr^{¶,*,**}, Piotr Major^{¶,*,**}, Ishan Aditya^{††}, Yonah Krakowsky^{‡‡}, Aristithes G. Doumouras^{†,‡}, Scott Gmora^{†,‡}, Mehran Anvari^{†,‡} and Dennis Hong^{†,‡}



- Bariatric surgery results in **47%** (95% CI 34–60%) improvement in SUI.
- The quality of evidence was very low for all outcomes

Pelvic floor muscle training ?

- [illegible]

Study protocol | [Open access](#) | Published: 05 June 2023


Effect of pelvic floor muscle training on reports of urinary incontinence in obese women undergoing a low-calorie diet before bariatric surgery — protocol of a randomized controlled trial



Pauliana C. S. Mendes, Tatiana B. Fretta, Milena F. C. Camargo, Patricia Driusso & Cristine Homsj Jorge 

Trials 24, Article number: 376 (2023) | Cite this article

Human Amniotic Fluid Stem Cell-derived Muscle Progenitor Cell Therapy for Stress Urinary Incontinence

Samples of 10 mL amniotic fluid were obtained with informed consent from 4 women who were undergoing amniocentesis for prenatal diagnosis at 15-19 weeks of pregnancy. The amniotic fluid was centrifuged and the pellets were resuspended in the Chang Medium (α -MEM, 15% embryonic stem cell-fetal bovine serum [Gibco-In-vitrogen, Grand island, NY, USA] with 18% Chang B and 2% Chang C [Irvine Scientific, Irvine, CA, USA]) and placed on a petri dish. Non-adherent cells were discarded at 1 week. Adherent cells were passaged for expansion when they reached 80% confluence. The culture medium was replaced every 3 days.





Ctrl(-): pudendal neurectomy without cell injection.

Improved Leak point pressure(LPP) and Closing pressure(CP) 2 and 4 weeks after transplanatation.



Therapeutic Potential of Adipose-derived Stem Cell-based Microtissues in a Rat Model of Stress Urinary Incontinence




Meng Li,¹ Guangyong Li,¹ Hongen Lei, Ruili Guan, Bicheng Yang, Zhezhu Gao, Yu Hui, Fubao Chen, and Zhongcheng Xin

During the ovariectomy, ADSCs were isolated from para-ovary fat and cultured

28-days after cell injection



A



B





Figure 1. Immunohistochemistry and bar graph showing MHC expression in the striated muscle layer. The Sham group shows a significantly higher value (approx. 16) compared to the SUI group (approx. 5). The ADSCs group (approx. 9) and MTs group (approx. 14) show intermediate values. Statistical significance is indicated by asterisks (*, #) and error bars.

被科學文獻紀錄，接受未經證實的幹細胞療法的案例

性別	年紀	居住國	提供治療地	疾病狀態	細胞療法	注射部位	併發症
男	13	以色列	莫斯科診所	共濟失調微血管擴張症候群	胎兒神經幹細胞	直接注射小腦及腦脊液	腫瘤
女	46	泰	泰國私人診所	狼瘡性腎病	造血幹細胞	經皮直接注射兩腎	腫瘤
女	17	美	哥斯大黎加	多發性硬化症	異體臍帶血幹細胞 自體脂肪幹細胞	鞘內注射和靜脈輸注	神經性
男	66	美	中國、阿根廷 墨西哥的診所	缺血性中風	間質幹細胞、胚胎幹細胞、胎兒神經幹細胞	鞘內注射	腫瘤
女	63	美	美	整容	腹部脂肪	臉部注射	感染
女	18	美	葡萄牙	脊椎損傷	嗅黏膜細胞	脊椎管內移植	腫瘤
女	73	美	美	老化性黃斑部病變	自體脂肪幹細胞	水晶體內注射	失明
不明	22	西方人	中	脊髓損傷	嗅鞘胎兒細胞	脊椎注射	感染、消化道出血
女	27	埃及	埃及	急性橫貫性脊髓炎	間質幹細胞	鞘內注射	自體免疫反應(腦膜炎)
男	41	不明	不明	肥厚型心肌病	自體前驅細胞	心肌注射	心室顫動
男	41	不明	不明	頸椎椎間盤突出	脂肪幹細胞	靜脈注射	肺栓塞
女	71	不明	日本	慢性腎衰竭	脂肪幹細胞	靜脈注射	神經性

Therapeutic effects of Low intensity extracorporeal low energy shock wave therapy (LiESWT) on stress urinary incontinence

Cheng-Yu Long^{1,2,3,4,11}, Kun-Ling Lin^{1,4,11}, Yung-Chin Lee^{5,6,7}, Shu-Mien Chuang^{5,8}, Jian-He Lu^{5,7}, Bin-Nan Wu⁹, Kuang-Shun Chueh^{5,10}, Chin-Ru Ker¹, Mei-Chen Shen⁵ & Yung-Shun Juan^{3,5,7,10*}



Ö □

W4

Ö □

F1

Timetable	2 weeks	1 week	4 weeks	1 week	4 weeks	1 week	1 month
	▲	▲	▲	▲	▲	▲	▲
	Screening	Run in		Treatment		End of treatment	End of recovery
							End of study

Subjects	Washout	Assessment (W0) (pre-treatment) (Baseline data)	LiESWT treatment	Assessment (W4) (post-treatment)	LiESWT treatment	Assessment (W8) (post-treatment)	Follow up (F1)
50 women of stress urinary incontinence (SUI) A single-arm prospective clinical trial		1. Questionnaires: OABSS, ICIQ-SF, UDI-6 and IIQ-7 score 2. Uroflowmetry and PVR. 3. 3-day voiding diary 4. Pad test	LiESWT (weekly): 3000 pulses, 0.25mJ/mm ² , and 3 pulses/second Once/week, Middle of labia minora: 1000 pulses Right side of labia minora: 1000 pulses Right side of labia minora: 1000 pulses	1. Questionnaires: OABSS, ICIQ-SF, UDI-6 and IIQ-7 score 2. Uroflowmetry and PVR. 3. 3-day voiding diary 4. Pad test 5. Kegel Exercise training	LiESWT (weekly): 3000 pulses, 0.25mJ/mm ² , and 3 pulses/second Once/week. Middle of labia minora: 1000 pulses Right side of labia minora: 1000 pulses Right side of labia minora: 1000 pulses	1. Questionnaires: OABSS, ICIQ-SF, UDI-6 and IIQ-7 score 2. Uroflowmetry and PVR. 3. 3-day voiding diary 4. Pad test 5. Kegel Exercise training	1. Questionnaires: OABSS, ICIQ-SF, UDI-6 and IIQ-7 score 2. Uroflowmetry and PVR. 3. 3-day voiding diary 4. Pad test 5. Kegel Exercise training

Take home message

- 肥胖透過增加腹壓、骨盆底肌壓迫、荷爾蒙變化、細胞內脂肪累積、全身性發炎等造成尿道括約肌萎縮導致尿失禁。
- 減重約 10% 體重重量可減低漏尿頻率約 50%
- 透過減重手術如 RYGB 或 Sleeve 亦可達到類似效果
- 肥胖病人漏尿仍可接受尿道中段懸吊手術，滿意度高，失敗率較不肥胖者高。
- 肥胖病人漏尿手術失敗，可能原因為吊帶過鬆或移位。



©N-7443/444N-01-747=77=N

台大醫院
新竹台大分院



吳晉睿醫師